U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799338) titled 'Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France' on Jan. 23.
Brief Summary: For most people with HIV (PWH), an effective antiretroviral regimen can be devised. However, some PWH have multiple treatment failures due to viral resistance or unacceptable side effects to medication and no longer have durable viral suppression. People with multidrug-resistant HIV-1 are at increased risk for hospitalization, progression to acquired immunodeficiency syndrome, and death.
Lenacapavir (LEN) is a first-in-class capsid inhibitor and has been evaluated through the CAPELLA phase 3 trial in PWH with replica...